The physiologic basis for anticytokine clinical trials in the treatment of sepsis

Journal of the American College of Surgeons

Volumn 186, Issue 3, 1998, Pages 337-350

  Cain, Brian S ^a   Meldrum, Daniel R ^a   Harken, Alden H ^a   McIntyre Jr , Robert C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ENDOTOXIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; LISOFYLLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAK 195 F; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDIC ACID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; HUMAN; HYPERTHERMIA; HYPOTENSION; HYPOTHERMIA; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; TACHYCARDIA; TACHYPNEA;

EID: 0031940217     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(98)00036-2     Document Type: Article

References (163)

1. Barrie PS, and Hydo LJ. Influence of multiple organ dysfunction syndrome on duration of critical illness and hospitalization. Arch Surg 1996;131:1318-1324.
2. Bone RC. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993;6:57-68.
3. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-242.
4. Bone RC, Fisher CJ, Slotman GJ, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-658.
5. Bernard GR, Reinnes HD, and Russell JA. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-918.
6. Parrillo JE. Pathogenic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477.
7. Lynn WA, and Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995;20: 143-158.
8. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
9. Borrelli E, Roux-Lombard P, Grau GE, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996;24:392-397.
10. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-gamma in the serum of patients with septic shock. J Immunol 1990;161:982-987.
11. Debets JM, Kampmeijer R, VanDerLinden MP, et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989;17:489-494.
12. Waage A, Halstensen A, and Espevik K. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-357.
13. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in human endotoxinemia and primate bacteremia. Surg Gynecol Obstet 1988;166:147-153.
14. Mitchie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1481-1486.
15. van der Poll T, van Deventer SJH, Hack CE, et al. Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood 1992;79:693-698.
16. van der Poll T, Romjin JA, Endert E, et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991;261:E457-E465.
17. van der Poll T, Bueller HR, tenCate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1627.
18. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234: 470-474.
19. Ferrari-Baliviera E, Mealy K, Smith RJ, et al. Tumor necrosis factor induces adult respiratory distress syndrome in rats. Arch Surg 1989;124:1400-1405.
20. Beutler B, Milsark IW, and Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985;229:869-871.
21. Freudenberg MA, and Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and grampositive bacteria in E-galactosamine treated mice. Infect Immunol 1991;59:2110-2115.
22. Hinshaw LB, EmersonTE, Taylor FB, et al. Lethal Staphylococcus aureas shock in primates: prevention of death with anti-TNF antibody. J Trauma 1992;33:568-573.
23. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662-664.
24. Shapiro L, Clark BD, Orencole SF, et al. Detection of tumor necrosis factor soluble receptor p55 (TNFRp55) in blood samples from healthy and endotoxemic humans. J Infect Dis 1993;167:1344-1350.
25. Spinas GA, Keller U, and Brockhaus M. Release of soluble tumor necrosis factor in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;90:533-536.
26. vanZee KJ, Kohno T, Fisher E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-alpha in vivo and in vitro. Proc Natl Acad Sci USA 1992;89: 4845-4849.
27. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991;21: 2883-2886.
28. Dinarello CA, Gelfand JA, and Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-1835.
29. Last-Barney K, Roman CA, Faanes RB, et al. Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1. J Immunol 1988;141:527-530.
30. Beutler B, and Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987;316:379-385.
31. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989;44:153-205.
32. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of IL-1. J Exp Med 1986;163:1433-1450.
33. Tewari A, Buhles WC, and Starnes HF. Preliminary report: effects of interleukin-1 on platelet counts. Lancet 1990;336:712.
34. Tewari A, and Starnes HF. Retraction: effects of interleukin-1 on platelet counts. Lancet 1992;340:496.
35. Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988;81:1162-1172.
36. Fisher E, Marano MA, Zee KJV, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in E coli septic shock, but fails to alter host responses to sublethal endotoxinemia. J Clin Invest 1992;89:1551-1557.
37. Alexander HR, Doherty GM, Buresh CM, et al. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxinemia in mice. J Exp Med 1991;173:1029-1032.
38. Ohlsson K, Bjork P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-552.
39. Wakabayashi G, Gelfand JA, Burke JF, et al. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock. FASEB J 1991;5:338-343.
40. Dripps DJ, Brandhuber BJ, Thompson RC, et al. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate signal transduction. J Biol Chem 1991;266: 10331-10336.
41. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1 -receptor antagonist during experimental endotoxinaemia. Lancet 1991;338:1423-1424.
42. Fisher E, Zee KJV, Marano M, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992;79:2196-2200.
43. Gershenwald JE, FongYM, Fahey TJI, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990;87:4966-4970.
44. Symons JA, Eastgate JA, and Duff GW. Purification and characterization of a novel soluble receptor for IL-1. J Exp Med 1991;174:1251-1254.
45. Orencole SF, Vannier E, and Dinarello CA. Detection of soluble IL-I receptor type II (IL-1sRII) in sera and plasma from healthy volunteers. Cytokine 1994;6:554.
46. Giri JG, Wells J, Dower SK, et al. Elevated levels of shed type II IL-1 receptor in sepsis. J Immunol 1994;153:5802-5809.
47. Fanslow WC, Simms JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990;248:739-742.
48. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-1652.
49. Kumar A, Thota V, Dee L, et al. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;3:949-958.
50. Moldawer LL. Biology of proinflammatory cytokines and their antagonists. Crit Care Med 1994;22:S3-S7.
51. Jansen MJ, Hendriks T, Vogels MT, et al. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit Care Med 1996;24:1196-1202.
52. Dinarello CA. Role of interleukin-1 in infectious disease. Immunol Rev 1992;127:119-146.
53. Hack CE, DeGroot ER, Felt-Bersma RJF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989:74:1704-1710.
54. Partrick DA, Moore FA, Moore EE, et al. The inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure. Am J Surg 1996;172:425-431.
55. Biffl WL, Moore EE, Moore FA, et al. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996;224:647-664.
56. Faist E, Schinkel C, and Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996;20:454-459.
57. DeVries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995;27:537-541.
58. Endo S, Inada K, Arakawa N, et al. Interleukin 11 levels in patients with disseminated intravascular coagulation. Res Commun Mol Pathol Pharmacol 1996;91:253-256.
59. Munoz C, Cartlet J, Fitting C, et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754.
60. Kapadia S, Lee J, Torre-Amione G, et al. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995;96:1042-1052.
61. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary induced multisystem organ failure. Ann Thorac Surg 1993;56:S92-S96.
62. Boyle EM, Pohlman TH, Cornejo CJ, et al. Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion. Ann Thorac Surg 1996;62:1868-1875.
63. Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-1494.
64. Kapadia S, Torre-Amione G, Yokahama T, et al. Soluble TNF binding proteins modulate the negative inotropic properties of TNF alpha in vitro. Am J Physiol 1995;268:H517-H525.
65. Oral H, Kapadia S, Nakano M, et al. Tumor necrosis factor alpha and the failing human heart. Clin Cardiol 1995;8:IV20-IV27.
66. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
67. Colotta F, Dower SK, Simms JE, et al. The type II "decoy" receptor: a novel regulatory pathway for IL-1. Immunol Today 1994;15:562-566.
68. Seckinger P, Williamson K, Balavoine JF, et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1-alpha and 1-beta but not tumor necrosis factor-alpha. J Immunol 1987;139:1541-1545.
69. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-340.
70. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;545:167-227.
71. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in humans. Cytokine 1992;4: 353-360.
72. Granowitz EV, Porat R, Mier JW, et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxinemia in healthy humans. Blood 1993;82:2985-2990.
73. Suffredini AF, Reda D, Agosti J, et al. Cardiovascular and cytokine responses of normal humans following intravenous endotoxin and recombinant human tumor necrosis factor receptor (TNFR:Fc) [Abstract]. Intensive Care Med 1994;20:S147.
74. Suffredini AF, Reda D, Banks SM, et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-5054.
75. Hinshaw LB, Beller BK, Archer LT, et al. Recovery from lethal Escherichia coli shock in dogs. Surg Gynecol Obstet 1979;149: 545-553.
76. Hinshaw LB, Archer LT, Beller-Todd BK, et al. Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res 1980;28:151-170.
77. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble TNF receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151: 6602-6607.
78. Wooley PH, Whalen JD, Chapman DL, et al. Influence of a recombinant human soluble TNF receptor FC fusion protein on type II collagen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-1314.
79. Elliott MJ, Maini RN, Feldman M, et al. Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;8930:1105-1110.
80. Bone RC, Fisher CJ, and Clemmer TP. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989;17:389-393.
81. Rangel-Frausto MSR, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-123.
82. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
83. Vincent JL. Dear SIRS, I'm sorry to say I don't like you . . . Crit Care Med 1997;25:372-374.
84. Exley AR, Cohen J, and Burman W Monoclonal antibodies to TNF-alpha in severe septic shock. Lancet 1990;335:1275-1277.
85. Vincent JL, Bakker J, Marecaux G, et al. Administration of antiTNF antibody improves left ventricular function in septic shock patients: results of a pilot study. Chest 1992;101:810-815.
86. Saravolatz LD, Wherry JC, Spooner C, et al. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to tumor necrosis factor-alpha. J Infect Dis 1994;169:214-217.
87. Dhainaut JF, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995;23:1461-1469.
88. Fisher SCJ, Opal SM, Dhainaut JF, et al. Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-327.
89. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
90. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995;273:934-941.
91. Wherry J, Wenzel R, Wunderink R, et al. Monoclonal antibody to human tumor necrosis factor (TNF MAb): multicenter efficacy and safety study in patients with the sepsis syndrome. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana, 1993.
92. Carlet J. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana, 1993.
93. Cohen J, and Carlet J. INTERCEPT: an international multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431-1440.
94. 2 fragment of anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1994;1:1237-1245.
95. Moller A, Emling F, and Blohm D. Monoclonal antibodies to human tumor necrosis factor-alpha: in vitro and in vivo applications. Cytokine 1990;2:162-169.
96. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebocontrolled, dose-ranging study. Crit Care Med 1996;24:773-742.
97. Fisher CJJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-1702.
98. Deitch EA. Tumor necrosis factor as the proximal mediator of sepsis - or this too will pass. Crit Care Med 1995;23:1457-1458.
99. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxinemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-1561.
100. Sadoff J. Soluble TNF receptors. Presented at the third International Congress of the Immune Consequences of Trauma, Shock, and Sepsis. Munich, Germany, 1994.
101. Natanson C, Hoffman WD, Suffredini AF, et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-783.
102. Abraham E. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. Presented at the second annual Autumnal Sepsis Meeting. Deauville, France, November 1995.
103. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277:1531-1538.
104. Bagby GJ, Plessala KJ, Wilson LA, et al. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991;163:83-88.
105. Echtenacher B, Falk W, Mannel DN, et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery of experimental peritonitis. J Immunol 1990;145:3762-3766.
106. Nakane A, Mingawa T, and Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988;56:2563-2569.
107. Murray DR, and Freeman GL. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1995;78:154-160.
108. Riche F, Panis Y, Laisne MJ, et al. High tumor necrosis factor serum level is associated with increased survival in patients with abdominal septic shock: a prospective study in 59 patients. Surgery 1996;120:801-807.
109. Mastroeni P, Arena A, Costa GB, et al. Serum TNF alpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNF alpha antibodies. Microb Pathog 1991;11:33-38.
110. vanFurth R, vanZwet TL, Buisman AM, et al. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 1994;170:234-237.
111. Havell EA. Evidence that TNF has an important role in antibacterial resistance. J Immunol 1989;143:2894-2899.
112. Allendoerfer R, Magee DM, Smith JG, et al. Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J Infect Dis 1993;167:1168-1172.
113. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Nad Acad Sci USA 1997;94: 8093-8098.
114. Steinshamn S, Bemelmans MH, vanTits LJ, et al. TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. J Immunol 1996;157:2155-2159.
115. Heumann D, Roy DL, Zanetti G, et al. Contribution of TNF/ TNF receptor and of Fas ligand to toxicity in murine models of endotoxemia and bacterial peritonitis. J Inflamm 1995;47:173-179.
116. Echtenacher B, Mannel DN, and Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75-77.
117. Amiot F, Boussadia O, Cases S, et al. Mice heterozygous for a deletion of the tumor necrosis factor-alpha and lymphotoxin-alpha genes: biological importance of a nonlinear response of tumor necrosis factor-alpha to gene dosage. Eur J Immunol 1997;27:1035-1042.
118. Conlan JW. Neutrophils and tumour necrosis factor-alpha are important for controlling early gastrointestinal stages of experimental murine listeriosis. J Med Microbiol 1997;46:239-250.
119. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gramnegative sepsis. J Exp Med 1994;180:2173-2179.
120. Carter DB, Diebel MR, Dunn CJ, et al. Purification, cloning, expression, and biological characterization of an interleukin 1 receptor antagonist protein. Nature 1990;344:633-638.
121. Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled, multicenter trial. Crit Care Med 1994;22: 12-21.
122. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-1843.
123. Knaus WA, Harrell F, Fisher CJJ, et al. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA 1993;270:1233-1241.
124. Havell EA, Moldawer LL, Helfgott D, et al. Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol 1992; 148: 1486-1492.
125. Fantuzzi G, and Dinarello CA. The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol 1996;59:489-493.
126. Kozak W, Zheng H, Conn CA, et al. Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1 betadeficient mice. Am J Physiol 1995;269:R969-R977.
127. Symons JA, Young PR, and Duff GW Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714-1718.
128. Dower SK, Faanslow W, Jacobs C, et al. Interleukin IL-1 antagonists. Ther Immunol 1994;1:113-122.
129. Mullarkey MF, Leiferman KM, Peters MS, et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994;152:2033-2041.
130. Preas HL, Reda D, Tropea M, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996;88:2465-2472.
131. Moore FA, Feliciano DV, Andrassy RJ, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. Ann Surg 1992;216: 172-183.
132. Zeni F, Freeman B, and Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-1100.
133. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-1128.
134. DeWaalMalefyt R, Abrams J, Bennet B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human myocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
135. Viera P, DeWaalMalefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Nad Acad Sci USA 1991;88:1172-1176.
136. Howard M, Muchamel T, Andrade S, et al. Interleukin 10 protects mice from lethal endotoxinemia. J Exp Med 1993;177: 1205-1208.
137. Gerard C, Bruyns C, Marchant D, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxinemia. J Exp Med 1993;177:547-550.
138. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. J Immunol 1995;154:5492-5499.
139. Trepicchio WL, Bozza M, Pedneault G, et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996;157:3627-3634.
140. Redlich CA, Gao X, Rockwell S, et al. IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 1996;157:1705-1710.
141. Yang YC, and Yin T. Interleukin (IL)-11-mediated signal transduction. Ann NY Acad Sci 1995;762:31-40.
142. Chang M, Williams A, Ishizawa L, et al. Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats. Blood Cells Mol Dis 1996;22:57-67.
143. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-3624.
144. Forstermann U, Pollock J, Schmidt H, et al. Calmodulin-dependent endothelium-derived relaxing factor/nitric synthase activity is present in the paniculate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88: 1788-1792.
145. Gross SS, Jaffe EA, Levi R, et al. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterine-dependent, calmodulin-independent, and inhibited by arginine analogues with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun 1991;178:823-829.
146. Palmer RMJ. The discovery of nitric oxide in the vessel wall: a unifying concept in the pathogenesis of sepsis. Arch Surg 1993; 128:396-401.
147. Thiemermann C. Role of L-arginine-nitric oxide pathway in circulatory shock. Adv Pharmacol 1994;28:45-97.
148. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 1995;3:2-32.
149. Kilbourn RG, Szabo C, and Traber DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 1997;7:235-246.
150. Kilbourn R, Fonesca G, Price K, et al. Clinical evaluation of NG-methyl-L-arginine in cancer patients with shock. Presented at the fourth international meeting: Biology of Nitric Oxide. Amelia Island, Florida, 1995.
151. Zaccardelli D, Grover R, and Colice G. Hemodynamic effects of 546C88 (L-NG-methyl-L-arginine HCl) in an open label, dose escalation study of patients with septic shock. Presented at the eighth European Congress of Intensive Care Medicine. Athens, Greece, 1995.
152. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995;23: 259-264.
153. Daemen-Grubbels R, Groeneveld P, Groeneveld A, et al. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363-1370.
154. Haines KA, Reibman J, Tang XY, et al. Effects of protein I of Neisseria gonorrhoeae on neutrophil activation: generation of diacylglycerol from phosphatidylcholine via a specific phospholipase C is associated with exocytosis. J Cell Biol 1991;114:433-442.
155. Bursten S, Weeks R, West J, et al. Potential role for phosphatidic acid in mediating the inflammatory responses to TNFα and IL-1β. Cire Shock 1994;44:14-29.
156. Abraham E, Bursten S, Shenkar R, et al. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med 1995;181:569-575.
157. Rice GC, Rosen J, Weeks R, et al. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1994;1:254-266.
158. Waxman K, Daughters K, Aswani S, et al. Lisophylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Crit Care Med 1996;24:1724-1728.
159. Rice GC, Brown PA, Nelson RJ, et al. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci USA 1994;91:3857-3861.
160. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992;356:768-774.
161. Li P, Allen H, Banerjee S, et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 1995;80:401-411.
162. Miller EE, Krasney PA, Gauvin DM, et al. Inhibition of mature IL-1 beta production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1 beta converting enzyme. J Immunol 1995;154:1331-1338.
163. Fantuzzi G, Ku G, Harding MW, et al. Response to local inflammation of IL-1 beta-converting enzyme-deficient mice. J Immunol 1997;158:1818-1824.